Heat Biologics Inc (HTBX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Heat Biologics Inc (HTBX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9785
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Heat Biologics Inc (Heat Biologics) is a biopharmaceutical company which develops novel immuno therapeutics for the treatment of cancer. Its pipeline encompasses viagenpumatucel-L based investigational candidate targeted at the treatment of non-small cell lung cancer, and co-stimulatory antibodies targeted at hematologic malignancies, and other tumors. The co-stimulatory antibodies harness human body’s natural antigen specific immune response to reprogram the immune system to offer durable clinical outcomes. Heat Biologics’ off-the-shelf therapies are based on its proprietary T-cell activating platform (TCAP), which turns immunologically cold tumors hot. It has subsidiaries in the US, Germany, and Australia. Heat Biologics is headquartered in Durham, North Carolina, the US.

Heat Biologics Inc (HTBX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heat Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Heat Biologics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Heat Biologics Raises USD0.5 Million in Venture Funding 12
Heat Biologics Raises US$5 Million In Venture Financing 13
Partnerships 14
Selexis and Pelican Therapeutics Enter into Agreement 14
Heat Biologics Enters into Agreement with Adaptive Biotechnologies 15
Licensing Agreements 16
University of Miami Enters into Licensing Agreement with Heat Biologics 16
Shattuck Labs Enters into Licensing Agreement with Heat Biologics 18
Heat Biologics Enters into Licensing Agreement with Columbia University 19
Heat Biologics Enters into Licensing Agreement for Multiple Myeloma Cell Line 20
Heat Biologics Enters into Licensing Agreement with University of Miami 21
Equity Offering 22
Heat Biologics Files Registration Statement for Public Offering of Shares 22
Heat Biologics to Raise up to USD15 Million in Public Offering of Shares and Warrants 23
Heat Biologics Plans to Raise up to USD1.3 Million in Public Offering of Shares 24
Heat Biologics to Raise up to USD3.7 Million in Public Offering of Shares 25
Heat Biologics Prices USD2.5 Million of Public Offering of Shares 26
Heat Biologics Raises USD4 Million in Public Offering of Common Stock 27
Heat Biologics Raises USD7 Million in Public Offering of Shares 28
Heat Biologics Raises USD12.3 Million in Public Offering of Shares 30
Heat Biologics Completes Underwriters’ Partial Exercise Of Over-Allotment Option For IPO Of Shares For US$27 Million 32
Acquisition 34
Heat Biologics Acquires 80% Stake in Pelican Therapeutics 34
Heat Biologics Inc – Key Competitors 35
Heat Biologics Inc – Key Employees 36
Heat Biologics Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Aug 14, 2018: Heat Biologics reports second quarter 2018 results and provides corporate update 38
May 15, 2018: Heat Biologics Reports First Quarter 2018 Results and Provides Corporate Update 39
Feb 28, 2018: Heat Biologics Reports Fiscal Year 2017 Financial Results 40
Nov 13, 2017: Heat Biologics Reports Third-quarter 2017 Results and Corporate Update 41
May 11, 2017: Heat Biologics Provides Business and Clinical Update for the First Quarter of 2017 42
Mar 31, 2017: Heat Biologics Reports Fiscal Year 2016 Financial Results 44
Corporate Communications 46
Feb 28, 2018: Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards 46
Oct 23, 2017: Heat Biologics and its Pelican Therapeutics Subsidiary Appoint Two New Members to their Scientific Advisory Boards 47
Jul 03, 2017: Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics 48
Jan 04, 2017: Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer 49
Product News 50
10/30/2017: Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives Second Tranche of its $15.2 Million CPRIT Grant Award 50
06/28/2017: Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of $15.2 Million CPRIT Grant Award 51
03/16/2017: Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine 52
Clinical Trials 53
Nov 11, 2017: Heat Biologics Presents Follow-up Data on its ComPACT(TM) T-cell Stimulating Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Heat Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heat Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heat Biologics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Heat Biologics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Heat Biologics Raises USD0.5 Million in Venture Funding 12
Heat Biologics Raises US$5 Million In Venture Financing 13
Selexis and Pelican Therapeutics Enter into Agreement 14
Heat Biologics Enters into Agreement with Adaptive Biotechnologies 15
University of Miami Enters into Licensing Agreement with Heat Biologics 16
Shattuck Labs Enters into Licensing Agreement with Heat Biologics 18
Heat Biologics Enters into Licensing Agreement with Columbia University 19
Heat Biologics Enters into Licensing Agreement for Multiple Myeloma Cell Line 20
Heat Biologics Enters into Licensing Agreement with University of Miami 21
Heat Biologics Files Registration Statement for Public Offering of Shares 22
Heat Biologics to Raise up to USD15 Million in Public Offering of Shares and Warrants 23
Heat Biologics Plans to Raise up to USD1.3 Million in Public Offering of Shares 24
Heat Biologics to Raise up to USD3.7 Million in Public Offering of Shares 25
Heat Biologics Prices USD2.5 Million of Public Offering of Shares 26
Heat Biologics Raises USD4 Million in Public Offering of Common Stock 27
Heat Biologics Raises USD7 Million in Public Offering of Shares 28
Heat Biologics Raises USD12.3 Million in Public Offering of Shares 30
Heat Biologics Completes Underwriters’ Partial Exercise Of Over-Allotment Option For IPO Of Shares For US$27 Million 32
Heat Biologics Acquires 80% Stake in Pelican Therapeutics 34
Heat Biologics Inc, Key Competitors 35
Heat Biologics Inc, Key Employees 36
Heat Biologics Inc, Subsidiaries 37

List of Figures
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Heat Biologics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Heat Biologics Inc (HTBX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Samyang Biopharmaceuticals Corp-製薬・医療分野:企業M&A・提携分析
    Summary Samyang Biopharmaceuticals Corp (Samyang Biopharm) researches and develops technology platforms for drug delivery. Its product portfolio comprises transdermal patches, injections, ORC hemostat and others. The company spans its expertise in the development and distribution of biodegradable, s …
  • Complix NV:製薬・医療:M&Aディール及び事業提携情報
    Summary Complix NV (Complix) is a biopharmaceutical company that discovers and develops alphabodies and pre-clinical programs. The company’s products comprise CMPX-1023, a novel alphabody for autoimmune diseases, and cell penetrating alphabodies for the treatment of cancer, among others. It designs …
  • Chiyoda Corp (6366):企業の財務・戦略的SWOT分析
    Chiyoda Corp (6366) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • SM Prime Holdings, Inc.:企業の戦略・SWOT・財務情報
    SM Prime Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary SM Prime Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • IMCO Industries Ltd.:企業の戦略・SWOT・財務情報
    IMCO Industries Ltd. - Strategy, SWOT and Corporate Finance Report Summary IMCO Industries Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Pentair Plc (PNR):電力:M&Aディール及び事業提携情報
    Summary Pentair Plc (Pentair) is an industrial manufacturing company. It designs, manufactures and markets water treatment systems and high-performance products and solutions for filtration, separation and fluid process management. Its product portfolio includes point-of-entry and point-of-use filtr …
  • Slovenske elektrarne, a.s.:企業の発電所・SWOT分析2018
    Slovenske elektrarne, a.s. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key em …
  • Sulzer Ltd (SUN):電力:M&Aディール及び事業提携情報
    Summary Sulzer Ltd (Sulzer) is an industrial engineering company that manufactures and supplies pump equipment. It offers mixers, compressors, agitators and aeration equipment. The company provides repair and maintenance service solutions for turbines, pumps, compressors, motors, and generators. Sul …
  • Highland Gold Mining Limited
    Highland Gold Mining Limited - Strategy, SWOT and Corporate Finance Report Summary Highland Gold Mining Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Smiths Medical-医療機器分野:企業M&A・提携分析
    Summary Smiths Medical, a division of Smiths Group Plc, is a clinically-focused company, which manufactures medical devices used in various therapeutic, diagnostic and surgical procedures with focus on vital care, safety devices and medication delivery areas. The company’s product line consists of a …
  • Stellar Resources Ltd
    Stellar Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Stellar Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Alsalam Aerospace Industries:企業の戦略・SWOT・財務情報
    Alsalam Aerospace Industries - Strategy, SWOT and Corporate Finance Report Summary Alsalam Aerospace Industries - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Fluor Corporation (FLR)-石油・ガス分野:企業M&A・提携分析
    Summary Fluor Corporation (Fluor) is a global provider of engineering and construction services. Its service portfolio includes design, engineering, procurement, fabrication, modularization, construction, commissioning and maintenance, and project management solutions. It also offers other services …
  • Mapletree Commercial Trust Management Ltd:企業の戦略・SWOT・財務情報
    Mapletree Commercial Trust Management Ltd - Strategy, SWOT and Corporate Finance Report Summary Mapletree Commercial Trust Management Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Owens & Minor, Inc.:企業の戦略・SWOT・財務情報
    Owens & Minor, Inc. - Strategy, SWOT and Corporate Finance Report Summary Owens & Minor, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Zealand Pharma AS (ZEAL):製薬・医療:M&Aディール及び事業提携情報
    Summary Zealand Pharma AS (Zealand) is a biotechnology company that discovers, designs and develops peptide based medicines that targets specialty diseases. The company’s marketed products comprise Lyxumia and Suliqua for the treatment of Type 2 diabetes and others for the treatment of obesity and f …
  • NLC India Ltd:発電所・企業SWOT分析
    NLC India Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • Myriad Group AG:企業の戦略的SWOT分析
    Myriad Group AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Bactiguard Holding AB (BACTI B):医療機器:M&Aディール及び事業提携情報
    Summary Bactiguard Holding AB (Bactiguard) is a medical device manufacturer which develops and supplies infection protection solutions and antibiotics. The company’s product portfolio includes urinary catheters, foley catheters (BIP Foley catheters), endotracheal tubes and central venous catheters. …
  • International Drug Development Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary International Drug Development Institute (IDDI) is a healthcare institute that offers clinical data collection, analysis, trial design and trial reporting services. The institute offers biostatistical services and eClinical services and risk-based monitoring programs. Its biostatistical serv …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆